Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rash Add

Event · Clinical / regulatory
Product
ATR04-484
Indication
rash associated with KRAS and MEK inhibitors

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 29, 2026, 12:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AZTR
Bullish
medium confidence
Mentioned
$AZTR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AZTRBullishMed
01

Why it matters

The 8-K reports protocol amendments that broaden eligibility beyond EGFR inhibitor-associated rash to include KRAS and MEK inhibitor-associated rash, and NF1 patients with MEK-rash, alongside shorter washout periods to facilitate recruitment.

02

Market read

For AZTR, the key tradable takeaway is improved trial recruitment prospects via expanded eligibility and operational protocol changes, following advancement to Cohort 2.

03

What to watch

No new clinical data are disclosed; investors may need to wait for Cohort 2 safety/tolerability updates to validate that the expanded population responds similarly.

Relevance 6/10Novelty 6/10Timing: today’s SEC 8-K filing, ahead of Cohort 2 enrollment

Background

Azitra’s ATR04-484 is a topical live biotherapeutic candidate being studied in a multicenter Phase 1/2 trial, with Cohort 2 expected to enroll about 24 patients after a safety review committee recommendation.

Company-level read

Ticker impact

$AZTRBullishMedium confidence
Context

Azitra amended its ATR-04 Phase 1/2 protocol to expand eligibility for rash from KRAS and MEK inhibitors, plus NF1 with MEK-rash, and shortened washout periods.

Expected impact

Likely modest upside bias as investors price improved probability of enrollment completion and continued progression to Cohort 2.

Evidence & confidence

The filing is a primary clinical-trial protocol expansion with concrete operational changes (eligibility expansion, washout shortening) and links to Cohort 2 progression, but it does not provide new efficacy/safety results yet.

Market effects

Supports the precision dermatology and topical live biotherapeutic narrative by widening the addressable rash indications tied to targeted cancer therapies.

Limited, primarily affects US small-cap biotech sentiment.

Low, as the change is specific to a US clinical trial protocol and enrollment plan.

Counterpoint

Protocol expansion can increase heterogeneity of the patient population, potentially complicating safety signals or efficacy interpretation versus a narrower EGFR-rash cohort.

Key entities

  • Azitra, Inc.

    Clinical-stage biopharmaceutical company developing ATR04-484 for precision dermatology indications.

  • ATR04-484

    Topical live biotherapeutic product candidate being evaluated in Phase 1/2 for therapy-associated skin rashes.

  • ATR-04 Phase 1/2 clinical trial (NCT06830863)

    Randomized, double-blind, vehicle-controlled study evaluating safety, tolerability, bioavailability, pharmacodynamics, and preliminary efficacy.

Related articles

$AZTRMedAI 8/10

Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates

Azitra, Inc. (AZTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates BRANFORD, Conn. – November 12, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precis

$AZTRMedAI 8/10

Azitra to Present ATR-COSF Skin Model Results at BIO-Europe

Azitra (AZTR) will present ATR-COSF results, showing 56% wrinkle reduction and improved elasticity in ex vivo human skin models. The company expects initial human study results by year-end and has expanded its ATR-04 trial to include patients with rashes linked to KRAS and MEK inhibitors, targeting a larger patient population.

$AZTRMedAI 8/10

Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models

Azitra, Inc. (NYSE American: AZTR) will present research at BIO-Europe® showing ATR-COSF reduced fine lines and improved elasticity in ex vivo human skin models. Initial results from a first-in-human study are anticipated by year-end. The company also provided updates on its ATR-04 program for cancer treatment-associated rashes, expanding the trial to include additional patient groups.

$AZTRMedAI 8/10

Azitra expands trial eligibility for ATR-04 skin rash treatment

Azitra Inc. (NYSE American: AZTR) expanded its Phase 1/2 trial of ATR04-484 to include patients with rashes from KRAS/MEK inhibitors and NF1. The trial now has shorter washout periods for antibiotics and steroids. ATR04-484, a live biotherapeutic, has FDA Fast Track designation for cancer treatment-associated rash. The company aims to enroll 24 patients in Cohort 2 for a 28-day treatment period.